| NCT05980806 | A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | RECRUITING | PHASE2 | 2024-04-22 | 2028-10 | 2026-04 |
| NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | RECRUITING | PHASE3 | 2023-04-18 | 2028-01 | 2026-08 |
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | TERMINATED | PHASE2 | 2021-06-29 | 2022-06-24 | 2022-06-24 |
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | TERMINATED | PHASE2 | 2021-05-12 | 2023-09-22 | 2023-09-22 |
| NCT04562870 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-03-17 | 2026-09 | 2026-09 |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-03-11 | 2028-03 | 2026-03 |
| NCT04607772 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | WITHDRAWN | PHASE1, PHASE2 | 2020-11-18 | 2025-12 | 2025-12 |
| NCT04442022 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | PHASE2, PHASE3 | 2020-09-03 | 2025-12 | 2025-12 |
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | RECRUITING | PHASE2 | 2020-07-01 | 2028-01 | 2028-01 |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | TERMINATED | PHASE1, PHASE2 | 2020-06-08 | 2023-07-03 | 2023-07-03 |
| NCT04355676 | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 | WITHDRAWN | PHASE2 | 2020-04-30 | 2020-08-30 | 2020-08-30 |
| NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | COMPLETED | PHASE2 | 2020-04-17 | 2020-10-05 | 2020-10-05 |
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | COMPLETED | PHASE1, PHASE2 | 2020-01-14 | 2024-07-31 | 2024-07-31 |
| NCT03555422 | Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO] | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-01-05 | 2025-12 | 2022-01-22 |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | COMPLETED | PHASE3 | 2017-05-24 | 2022-05-12 | 2020-02-18 |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | TERMINATED | PHASE1 | 2016-06-08 | 2021-01-26 | 2021-01-26 |
| NCT02606461 | Selinexor in Advanced Liposarcoma | COMPLETED | PHASE2, PHASE3 | 2016-01-04 | 2021-10-26 | 2020-10-28 |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | COMPLETED | PHASE1, PHASE2 | 2016-01 | 2024-12-23 | 2024-08-31 |
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | WITHDRAWN | PHASE2 | 2015-12 | 2018-06 | 2017-06 |
| NCT02431351 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | WITHDRAWN | PHASE2 | 2015-11 | 2019-05 | 2017-12 |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | RECRUITING | PHASE1, PHASE2 | 2015-10 | 2027-04 | 2027-04 |
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | WITHDRAWN | PHASE1, PHASE2 | 2015-07 | 2018-02 | 2018-01 |
| NCT02431364 | Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults | TERMINATED | PHASE1 | 2015-05-26 | 2015-10-01 | 2015-10-01 |
| NCT02336815 | Selinexor Treatment of Refractory Myeloma | COMPLETED | PHASE2 | 2015-05-26 | 2019-07-26 | 2019-07-26 |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | TERMINATED | PHASE2 | 2015-02 | 2016-02 | 2016-01 |
| NCT02367690 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients | WITHDRAWN | PHASE1, PHASE2 | 2015-01 | 2015-09 | 2015-05 |
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | TERMINATED | PHASE2 | 2014-11-14 | 2016-08-31 | 2016-08-31 |
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | RECRUITING | PHASE2 | 2014-11 | 2027-11 | 2027-04 |
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | TERMINATED | PHASE2 | 2014-09-22 | 2015-12-10 | 2015-12-10 |
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | TERMINATED | PHASE2 | 2014-05 | 2016-04-01 | 2016-04-01 |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | COMPLETED | PHASE2 | 2014-04-09 | 2017-03-29 | 2017-01-24 |
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | TERMINATED | PHASE2 | 2014-03-03 | 2020-01-23 | 2020-01-23 |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML | COMPLETED | PHASE2 | 2014-03 | 2018-01-08 | 2018-01-08 |
| NCT01896505 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma | COMPLETED | PHASE1 | 2013-07-30 | 2016-10-21 | 2016-10-21 |
| NCT01607892 | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | COMPLETED | PHASE1 | 2012-07-23 | 2015-10-13 | 2015-10-13 |
| NCT01607905 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | COMPLETED | PHASE1 | 2012-06-18 | 2016-03-15 | 2016-03-15 |